Daljeet Kohli, head of research at IndiaNivesh Securities, says various positives related to Jubilant Life Sciences outweigh the negatives such as currency weakness. The company's pharma business is expected to continue its profitability going ahead and investors may buy the stock for an upside towards Rs 397-400.